StockWatch
·
ARVAYA · Q2 FY27 · THE VERDICT

Beds Multiply, Occupancy Stalls—And Margins Get Thinner

Reported profit soared 541%, but it's off a vanishingly small base. The real story: occupancy fell to 38% from 48% despite bed expansion, leaving the ₹1.4 Cr PAT vulnerable to any cost bump. Management's confidence in long-term upside rests on a single bet: will new hospitals ramp.

Q2 FY27 resultsARVAYABIJOY HANS LTD.20 Nov 2026 · 6 min read
Revenue Q2

₹40.3 Cr

✓ Claim ₹40 Cr delivered

Reported PAT

₹1.4 Cr

+541.6% YoY (off ₹0.2 Cr base)

NPM

3.4%

Paper-thin; zero cost cushion

Occupancy

38%

−10pp YoY; new units 27%

On paper, PAT jumped over 5× year-on-year. In substance, Arvaya delivered its first full consolidated quarter with occupancy compressed from 48% to 38%—the defining tension of the results. The company added 255 beds in six months, but new hospitals are running at 27% occupancy while mature units hold 46–56%. That spread is the occupancy ramp risk that management must solve, and it's what the market is pricing.

Claims vs. what holds up

Management's major assertions: verified against delivered result

Q2 revenue ₹40 Cr

Delivered ₹40.3 Cr

Supported

PAT ₹1.37 Cr

Delivered ₹1.4 Cr

Supported (minor rounding)

EBITDA margin 13% sustainable

Q2 OPM 13.0%; H1 13.1%

Supported

Occupancy fell to 38% from 48% YoY

517-bed base (up 255 YoY); new units 27%, mature 46–56%

Supported (explained but concerning)

ARPOB rose 17% YoY

Transcript: specialty mix shift to cardio, neuro, kidney, robotic surgery

Supported

Every core claim checks out. But the footnote matters: revenue growth masked occupancy dilution. Mature hospitals are firing (Hubballi at 56.5%, others 46–56%), but new acquisitions dragging at 27% are pulling the blended rate down. That's not fraud—it's transparency. The real question is velocity: how fast do new units ramp to 40–50%?

What changed on this call

  • Suhodha GI (Sigipl) acquired Nov 1 at ₹1 Cr/month revenue run-rate

  • Tech spend earmarked: ₹4.5 Cr capex (rights issue), ₹2–3 Cr annual cost going forward

  • MyArvaya app timeline set: go-live next quarter with patient engagement features

  • Occupancy compression now explicit (prior Q: implicit); 27% new units vs 48% mature units highlighted

  • No formal FY27 or FY28 revenue guidance; bed roadmap only (791 by Dec, 2,400 by FY30)

How the street is positioned

The stock has priced in disappointment. At ₹101.65, Arvaya is trading 29.9% below its all-time high of ₹145, and sitting below both its 20-day (₹109.23) and 50-day (₹114.09) moving averages. RSI at 37.2 indicates oversold territory—not capitulation, but sellers have had the floor. Volume is normal; there's been no panic dumping.

Ownership tells a quieter story. Promoter stake has trimmed to 28.33% from 30.62% a quarter ago—a 229 basis point slide. FII and DII ownership remain at 0%. On a stock down 30% from ATH, the promoter stepping back (even slightly) signals no conviction at higher prices. This is not a bull's market; it's a wait-and-see market.

₹ per share
054.13108.27162.4145All-time high101.65Current109.23SMA 2020.552w low
Stock positioning: 29.9% below ATH, trading below key moving averages. Up 395.85% from 52-week low but that base was distressed.

The bull-bear ledger

What the bulls own
  • Bed expansion roadmap is quantified and on track (517 → 791 by Dec, 2,400 by FY30)

  • EBITDA margin protected at 13–14% despite occupancy ramp headwind

  • ARPOB up 17% YoY; specialty mix shift (cardio, neuro, kidney, robotic) is real and sticky

  • Asset-light lease model reduces capex friction and balance-sheet strain

  • Government business (15–20% of revenue) provides stable occupancy base

What bears are circling
  • Occupancy fell to 38% from 48% YoY despite bed additions—a 10pp hit

  • New units stuck at 27% occupancy; path to 40–50% ramp is assumed, not proven

  • NPM 3.4% is hair-thin; zero room for wage or energy cost inflation

  • Tech spend (₹4.5 Cr capex + ₹2–3 Cr annual) has no proven monetization timeline; MyArvaya engagement-first, revenue later

  • Diagnostic network plans vague; analysts' probes on lab/imaging rollout got deflected ('in pipeline, can't disclose')

Risks ranked by what should concern a holder

Five risks: severity and why each matters

Occupancy ramp-up stalls

HIGH

New units at 27% need to reach 40–50% by FY28 for margin upside. If they plateau at 30–35%, PAT margins compress further, and the HMO thesis loses its scale lever.

PAT margin erosion on cost inflation

MEDIUM

NPM 3.4% leaves zero cushion. Hospital wage and energy costs are rising. Any inflation not offset by ARPOB growth hits earnings hard.

Tech monetization misses

MEDIUM

₹4.5 Cr capex + ₹2–3 Cr annual cost on MyArvaya is committed spend. If engagement doesn't translate to revenue by FY28, it becomes a drag, not a growth engine.

MoU pipeline execution slips

MEDIUM

220 beds signed (Jalna, Sangli, Shivamogga). If fit-out or operationalization delays push into FY28, the 2,400-bed FY30 target becomes a stretch.

Geographic concentration

LOW

Hubballi (56.5% occupancy) is the flag-bearer. Interstate expansion is unproven. Single-state dependency on Karnataka/Maharashtra limits optionality.

The debate

What to watch next

  • 1 · December 2026 bed milestone

    Does Arvaya hit the 791-bed target by year-end? This is the first quantified waypoint. Hit = confidence in execution; miss = red flag on integration velocity.

  • 2 · Q3 FY27 results: occupancy and MyArvaya launch

    New units' occupancy trend is the lynchpin. Any improvement toward 35%+ justifies the ramp thesis. MyArvaya's patient-engagement metrics matter: are 30,000+ SeCURE records in app, and is adoption tracking for external revenue?

  • 3 · FY28 EBITDA margin hold

    If occupancy drifts to 35–37% and EBITDA margin stays 13–14%, the HMO model works at scale. If margin slips to 12% or below, cost inflation or unit economics are worse than management guided.

Arvaya is not a turnaround or a turbo—it's a consolidation franchise in its first full year as a combined entity. The quarter proves the bed strategy works (517 operational, +255 YoY) and EBITDA margins hold. What it also proves is that occupancy ramp is slower than a mature operator (38% vs 48% despite scale). The street's 30% drawdown from ATH reflects that trade-off: long-term upside is real, but near-term uncertainty is priced at a risk premium.

For a holder, the single number to track is occupancy in Q3. If new units cross 35%, the ramp thesis survives. If they stay near 27–30%, PAT margins stay under pressure, and the turnaround calendar extends. EBITDA margins will likely hold at 13–14%, but net profit—the number that matters—depends entirely on whether the Jalna, Sangli, and Shivamogga units operationalize on time and ramp faster than the first cohort.

Informational and educational content only. Not investment advice.